Dropping two drug candidates puts Genmab in a better position, says CEO

Genmab made a rare move during Q3 by scrapping two candidates. However, neither CEO Jan van de Winkel nor a Sydbank analyst think the decision will have much of an impact on the company's future.
CEO of Genmab Jan van de Winkel | Photo: PR/Genmab
CEO of Genmab Jan van de Winkel | Photo: PR/Genmab

It isn't every day that biotech company Genmab has to abandon a drug under development.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading